Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of intravenous Dapirolizumab Pegol (BIIB133) in relapsing multiple sclerosis
2019-001967-58Phase 2Completed
- Sponsor
- Biogen
- Start
- May 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapirolizumab pegol in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoint: Number of cumulative Gd-enhancing lesions. Started May 2020; status: completed.
02
Drugs
dapirolizumab pegol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-001967-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001967-58.